分化型甲状腺癌诊疗一体化:放射性碘及超越
本文综述诊疗一体化概念在分化型甲状腺癌中的应用,以放射性碘I-131为最早范例,阐述钠碘同向转运体(NIS)在诊断与治疗中的作用,并介绍全身碘闪烁扫描、SPECT-CT与FDG PET-CT在病灶定位与个性化治疗中的价值,以及放射性碘难治性疾病的分子治疗方向。
要点
- 诊疗一体化指用诊断性扫描确认需治疗部位、治疗后扫描确认已治疗,以实现肿瘤剂量概念。
- NIS表达是分化型甲状腺癌摄取放射性碘的基础,低分化细胞NIS常阴性且与葡萄糖转运体1表达呈反比。
- SPECT-CT显著提高了全身碘闪烁扫描的精确度和敏感度,可准确定位碘亲和与非亲和的病灶。
核心结论
- 分化型甲状腺癌的初始手术治疗后行放射性碘治疗仍是大多数患者达到治愈的主要手段,NIS阳性与阴性共同构成放射性碘诊疗一体化的关键环节,SPECT-CT有助于更个性化的治疗决策。
研究设计与样本
- 综述,检索范围与纳入文献原文未报告;内容涵盖诊疗一体化概念的历史、NIS在放射性碘诊疗中的作用、全身碘闪烁扫描与SPECT-CT及FDG PET-CT的应用现状,以及放射性碘难治性疾病的分子治疗。
诊断标准与关键数值
- NIS的存在或缺失通过全身碘闪烁扫描(WBS)或2-脱氧-2(18F)氟脱氧葡萄糖(FDG)PET-CT记录。
- NIS在低分化细胞中通常为阴性,且与葡萄糖转运体1型表达呈反比。
临床应用与阅片要点
- 放射性碘诊疗一体化基于NIS表达阳性的甲状腺细胞及分化型甲状腺癌细胞能成功摄取循环中的放射性碘,从而治疗残留与转移病灶。
- SPECT-CT可准确本地化碘亲和或非亲和的疾病灶,提高全身碘闪烁扫描的精确度和敏感度,有助于更个性化的治疗。
- 诊疗一体化需同时关注NIS阳性与阴性两方面,二者共同构成放射性碘治疗分化型甲状腺癌的诊疗一体化方法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The term theranostics is the combination of a diagnostic tool that helps to define the right therapeutic tool for specific disease. It signifies the "we know which sites require treatment (diagnostic scan) and confirm that those sites have been treated (post-therapy scan)" demonstrating the achievable tumor dose concept. This term was first used by John Funkhouser at the beginning of the 90s, at the same time the concept of personalized medicine appeared. In nuclear medicine, theranostics is easy to apply and understand because of an easy switch from diagnosis to therapy with the same vector. It helps in maximizing tumor dose and sparing normal tissue with high specific and rapid uptake in metastasis. The oldest application of this concept is radioactive iodine I-131 (RAI). The first treatment based on the theranostic concept was performed on thyroid cancer patients with RAI in 1946. From then on management of differentiated thyroid cancer (DTC) has evolved on the multimodality concept. We now use the term "our" patient instead of "my" patient to signify this. However, the initial surgical management followed by RAI as per the theranostics has remained the mainstay in achieving a cure in most of DTC patients. The normal thyroid cells metabolise iodine, the principle of which is utilized in imaging of the thyroid gland with isotopes of iodine. RAI treatment of DTC is based on the principle of sodium iodide symporter (NIS) expressing thyroid cells with DTC cells having the ability of trapping circulating RAI successfully helping in treatment of residual and metastatic disease. NIS is usually negative in poorly differentiated cells and is inversely proportional to Glucose transporter receptor Type 1 expression. Both positive and negative NIS are the key components of the theranostic approach in treatment of DTC. Presence or absence of NIS is documented by either whole body iodine scintigraphy (WBS) or 2-deoxy-2(18F) fludeoxyglucose (FDG) positron emission tomography computed tomography (PET-CT). Currently, single photon emission CT and CT (SPECT-CT) has significantly improved the precision and sensitivity of whole body iodine scintigraphy with its capability of accurate localization of disease foci whether iodine avid or non-avid. This has helped in a more personalized approach in treatment. This review will give an overview of the role of NIS in the theranostic approach to management with RAI, its current status and also the molecular approach to treatment in RAI refractory disease.
引用
- Choudhury PS, Gupta M. Differentiated thyroid cancer theranostics: radioiodine and beyond. Br J Radiol. 2018. PMID: 30260232. doi:10.1259/bjr.20180136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。